Table 2.
Comparison of James Cook University Hospital outcomes with landmark three-dimensional radiotherapy trials.
| Trial | Radiotherapy regimen | Overall survival (%) | Colostomy-free survival (%) | Disease-free survival (%) | Grade 3+ acute toxicity (%) | ||||||
| 3 years | 5 years | 3 years | 5 years | 3 years | 5 years | GI | GU | Derm. | Acute NH | ||
| JCUH | 50.4 in 28 fx and 54 Gy in 30 fx | 76 (68–84)a | 68 (59–79)a | 85 (78–93)a | 85 (78–93)a | 68 (60–78)a | 59 (49–70)a | 12 | 0 | 51 | 56.2 |
| ACT Ib | 45 Gy in 20-25 fx | 65 | 53 | NA | NA | 39 | 41 | 14 | 3 | 50 | 67c |
| RTOG 98-11 | 45-50.4 Gy in 1.8 Gy per fx ± 5–8 Gy boost | NA | 78 | 90 | 90 | 67 | 60 | 36 | 3 | 49 | 74 |
| ACT IId,e | 50.4 Gy in 28 fx | NA | 79 | NA | 68 | NA | 69 | 16 | 1 | 48 | 62 |
Derm., dematological; fx, fractions; GI, gastrointestinal; GU, genitourinary; NH, non-haematological; JCUH, James Cook University Hospital; RTOG, Radiation Therapy Oncology Group.
aBrackets: 95% confidence interval.
bClassified severity of acute toxicity as ‘mild, moderate or severe’.13
c‘Severe’.
dACT II followed up acute toxicity until 4 weeks post-chemoradiotherapy and counted death as an event in colostomy-free survival.
eMitomycin group.